Cette année, la Société offre un vote contraignant sur la politique de rémunération 2017 de son Directeur Général pour la première fois et dans le cadre de la nouvelle loi "Sapin II" (résolution 14).
Proxinvest recommande aux actionnaires de s’opposer à cette résolution étant donné que la Société ne communique pas la politique de rémunération de son dirigeant pour l’exercice, ni les montants qui y sont attachés.
En ce qui concerne les autorisations d'augmentation du capital, la Société ne suspend toujours pas ces opérations en période d'offre publique. Ces résolutions peuvent donc être assimilées à des dispositifs anti-OPA et de ce fait, vont à l'encontre de notre politique de vote. De plus, la résolution 20 propose d’offrir un décoté de 15% les nouveaux entrants au capital, ce qui viendrait diluer de manière excessive les actionnairs.
Proxinvest recommande donc aux actionnaires de ne pas approuver la majorité de ces autorisations.
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora. Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus...
Item 1: Approve the share consolidation The Board requests shareholder approval to implement a share consolidation on the basis of 19 new ordinary shares for every 20 existing ordinary shares held. The consolidation is intended to maintain comparability, as far as possible, of the Company’s share price before and after the payment of a special dividend of $2.621 per share. The special dividend is equivalent to 5% of the market capitalisation of the Company as at 14 December 2018. The Company has implemented a series of share consolidations, returning funds to shareholders in this way in 2012...
Item 1: Approve Share Buybacks Shareholder approval is being sought to authorise the Company to make market purchases of its ordinary shares following the inclusion of a typographical error in the resolution granting authority at the 2018 AGM. This error meant that the authority granted at that meeting has already expired. As there is currently no authority in place, the Board proposes the standard share repurchase authority for the UK market with period ending until the earlier of 25 October 2019 (being the later date set out in in the resolution granting authority at the 2018 AGM) and the ...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.